Eagle Asset Management Inc. Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Eagle Asset Management Inc. trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 16.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,602 shares of the company’s stock after selling 12,657 shares during the quarter. Eagle Asset Management Inc. owned about 0.22% of Krystal Biotech worth $12,696,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC lifted its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech during the 2nd quarter valued at about $28,000. Key Financial Inc purchased a new stake in shares of Krystal Biotech in the second quarter valued at about $28,000. Blue Trust Inc. increased its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Krystal Biotech during the third quarter worth about $53,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Stock Performance

Shares of KRYS opened at $190.40 on Friday. The stock has a market capitalization of $5.48 billion, a PE ratio of 107.57 and a beta of 0.82. The company’s 50-day simple moving average is $179.54 and its 200-day simple moving average is $182.23. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue was up 879.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.67) EPS. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KRYS. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital lifted their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $202.29.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).